全文获取类型
收费全文 | 1901篇 |
免费 | 112篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 89篇 |
妇产科学 | 41篇 |
基础医学 | 205篇 |
口腔科学 | 59篇 |
临床医学 | 213篇 |
内科学 | 420篇 |
皮肤病学 | 55篇 |
神经病学 | 114篇 |
特种医学 | 288篇 |
外科学 | 194篇 |
综合类 | 27篇 |
一般理论 | 1篇 |
预防医学 | 92篇 |
眼科学 | 24篇 |
药学 | 81篇 |
中国医学 | 10篇 |
肿瘤学 | 103篇 |
出版年
2023年 | 11篇 |
2022年 | 14篇 |
2021年 | 45篇 |
2020年 | 25篇 |
2019年 | 46篇 |
2018年 | 52篇 |
2017年 | 30篇 |
2016年 | 27篇 |
2015年 | 37篇 |
2014年 | 49篇 |
2013年 | 64篇 |
2012年 | 90篇 |
2011年 | 91篇 |
2010年 | 72篇 |
2009年 | 84篇 |
2008年 | 72篇 |
2007年 | 62篇 |
2006年 | 65篇 |
2005年 | 47篇 |
2004年 | 46篇 |
2003年 | 44篇 |
2002年 | 42篇 |
2001年 | 46篇 |
2000年 | 40篇 |
1999年 | 37篇 |
1998年 | 53篇 |
1997年 | 55篇 |
1996年 | 67篇 |
1995年 | 49篇 |
1994年 | 46篇 |
1993年 | 54篇 |
1992年 | 39篇 |
1991年 | 18篇 |
1990年 | 29篇 |
1989年 | 48篇 |
1988年 | 39篇 |
1987年 | 45篇 |
1986年 | 40篇 |
1985年 | 28篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 26篇 |
1981年 | 22篇 |
1980年 | 9篇 |
1979年 | 9篇 |
1978年 | 6篇 |
1977年 | 15篇 |
1976年 | 13篇 |
1975年 | 15篇 |
1974年 | 5篇 |
排序方式: 共有2022条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
Susan E Krown Ping Li Jamie H Von Roenn Josephine Paredes Jie Huang Marcia A Testa 《Journal of interferon & cytokine research》2002,22(3):295-303
We wished to evaluate the efficacy and safety of a low and an intermediate daily dose of interferon-alpha2b (IFN-alpha2b) with didanosine in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma (KS). HIV-seropositive subjects with biopsy-confirmed cutaneous KS were randomized to receive either a low (1 million IU) or an intermediate (10 million IU) dose of IFN-alpha2b once daily with twice daily doses of didanosine. Treatment assignment was stratified by CD4 count. Response, toxicity, changes in CD4 counts, and survival were evaluated. Sixty-eight eligible subjects were accrued, 35 to low-dose and 33 to intermediate-dose IFN-alpha2b. The response rate was 40% in the low-dose group (95% CI, 24-58) and 55% in the intermediate-dose group (95% CI, 36-72) (p = 0.338). The median response duration was approximately 110 weeks in both groups. Intermediate-dose IFN induced grade 3/4 neutropenia more often (21% vs. 3%, p = 0.048) and grade 3/4 toxicity faster (p = 0.0231) and necessitated treatment discontinuation earlier for drug-related toxicities (p = 0.0416) than low-dose IFN. There were no significant differences in survival between the treatment groups. Baseline CD4 count was the only significant factor predicting response. Once-daily low-dose and intermediate-dose IFN-alpha2b induced similar response rates, which were achieved without optimal antiretroviral therapy. The slightly higher response rate in the intermediate-dose group was offset by its significantly poorer tolerance. These findings justify the use of lower, well-tolerated IFN doses for treatment of KS with currently used antiretroviral regimens. 相似文献
10.
The mammographic appearance of breast hamartoma, a benign cause of a breast mass, is characteristic. We present four cases from the University of Virginia to review the mammographic, pathologic, and clinical features of this unusual entity. 相似文献